Search - tctmd.com

Displaying 661 - 680 of 684

Sort: Relevancy | Date

Presentation SOLACI 2013

Clinical Trials Phases

Presenter: Alejandra Guerchicoff

July 24, 2013

Presentation TVT 2013

Unique Challenges of Supporting TAVR Clinical Trials

Presenter: Elizabeth Walsh

June 14, 2013

Presentation TCT 2013

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.

Presenter: Salvatore Cassese, Robert Byrne, Tomohisa Tada, Lamin King, Adnan Kastrati

January 31, 2013

Presentation Cell Therapy 2013

Clinical Trials for Non-Ischemic Cardiomyopathy: Rationale and Study Design

Presenter: Leslie Miller

January 24, 2013

Presentation AHA 2012

Rivaroxaban Use is Associated with Reduced Risk of Myocardial Infarction- Insights from a Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials

Presenter: Saurav Chatterjee

November 04, 2012

Presentation TCT 2012

Impact of FDASIA on Clinical Trials

Presenter: Ashley Boam

October 25, 2012

Presentation TCT 2012

Completed and Ongoing Clinical Trials

Presenter: Laura Mauri

October 25, 2012

Presentation TCT 2012

Transcatheter Pulmonary Valve Replacement: Clinical Trials and Real-world Experiences

Presenter: William Hellenbrand

October 25, 2012

Presentation TCT 2012

The Misinterpretation of Clinical Trials: Common Errors and Case Examples

Presenter: Sanjay Kaul

October 25, 2012

Presentation TCT 2012

The Dos and Don'ts of Initiating Prospective Randomized Clinical Trials

Presenter: Adnan Kastrati

October 25, 2012

Presentation TCT 2012

Late Breaking Clinical Trials: Venous Thromboembolic Disease EINSTEIN-PE (Rivaroxaban)

Presenter: Jeffrey Kuvin

October 23, 2012

Presentation TCT 2012

Late Breaking Clinical Trials: BRIDGE-ACS (Multimodality Approach to Adherence), INFUSE-AMI (STEMI), and IMMEDIATE (GIK)

Presenter: Ajay Kirtane

October 23, 2012

Presentation TCT 2012

Late Breaking Clinical Trials: ACRIN-PA (CTA in Low-Intermediate Risk Chest Pain) and ROMICAT II (CTA in Low-Intermediate Risk Chest Pain)

Presenter: Issam Mikati

October 23, 2012

Presentation TCT 2012

Balloon-Expandable vs. Self-Expanding vs. Covered Stents In Iliac Arteries: Insights from Clinical Trials and Clinical Practice

Presenter: Tony Das

October 23, 2012

Presentation TCT 2012

Late Breaking Clinical Trials: STAMPEDE (Bariatric Surgery) and PCSK9 (LDL Reduction)

Presenter: Elizabeth Jackson

October 23, 2012

Presentation TCT 2012

Late Breaking Clinical Trials: CORONARY (On-Pump vs. Off-Pump CABG), CPORT (Nonprimary PCI Without Surgical Backup), ASCERT (CABG vs. PCI), and TRAP2-TIMI 50 (Vorapaxar for...

Presenter: David Morrow

October 23, 2012

Presentation TCT 2012

What Definition Should Be Used to Define Periprocedural MI in Clinical Trials and Practice?

Presenter: Gregg Stone

October 22, 2012

Presentation TCT 2012

Phase II and III Clinical Trials: Off and Running!

Presenter: Amit Patel

October 22, 2012

Presentation TCT 2012

Calcified Lesions: New Insights in Stable CAD and ACS from Large-Scale Clinical Trials

Presenter: Philippe Genereux

October 22, 2012

Presentation TCT 2012

Is Myocardial Infarction a Reasonable or Relevant Endpoint to Assess Carotid Intervention and Stroke Prevention Therapies in Clinical Practice and Trials?

Presenter: Carlos Mena

October 22, 2012

Advertisement

Clinical Trials Phases

Unique Challenges of Supporting TAVR Clinical Trials

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.

Clinical Trials for Non-Ischemic Cardiomyopathy: Rationale and Study Design

Rivaroxaban Use is Associated with Reduced Risk of Myocardial Infarction- Insights from a Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials

Impact of FDASIA on Clinical Trials

Completed and Ongoing Clinical Trials

Transcatheter Pulmonary Valve Replacement: Clinical Trials and Real-world Experiences

The Misinterpretation of Clinical Trials: Common Errors and Case Examples

The Dos and Don'ts of Initiating Prospective Randomized Clinical Trials

Late Breaking Clinical Trials: Venous Thromboembolic Disease EINSTEIN-PE (Rivaroxaban)

Late Breaking Clinical Trials: BRIDGE-ACS (Multimodality Approach to Adherence), INFUSE-AMI (STEMI), and IMMEDIATE (GIK)

Late Breaking Clinical Trials: ACRIN-PA (CTA in Low-Intermediate Risk Chest Pain) and ROMICAT II (CTA in Low-Intermediate Risk Chest Pain)

Balloon-Expandable vs. Self-Expanding vs. Covered Stents In Iliac Arteries: Insights from Clinical Trials and Clinical Practice

Late Breaking Clinical Trials: STAMPEDE (Bariatric Surgery) and PCSK9 (LDL Reduction)

Late Breaking Clinical Trials: CORONARY (On-Pump vs. Off-Pump CABG), CPORT (Nonprimary PCI Without Surgical Backup), ASCERT (CABG vs. PCI), and TRAP2-TIMI 50 (Vorapaxar for...

What Definition Should Be Used to Define Periprocedural MI in Clinical Trials and Practice?

Phase II and III Clinical Trials: Off and Running!

Calcified Lesions: New Insights in Stable CAD and ACS from Large-Scale Clinical Trials

Is Myocardial Infarction a Reasonable or Relevant Endpoint to Assess Carotid Intervention and Stroke Prevention Therapies in Clinical Practice and Trials?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content